Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Latest Information Update: 20 Sep 2019
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms GOLDEN-3
- Sponsors Sunovion Respiratory Development
- 01 May 2019 According to a Sunovion Pharmaceuticals media release, data from GOLDEN 3 and 4 Studies will be presented at the American Thoracic Society International Conference 2019 (ATS 2019).
- 05 Dec 2017 According to a Sunovion Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution (25 mcg twice daily), also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- 31 Oct 2017 Results of pooled analysis from of the GOLDEN-3, GOLDEN-4 and GOLDEN-5 studies presented in a Sunovion Pharmaceuticals media release.